Todas las investigaciones
ReclutamientoExploratorio terapéutico (Fase II)Intervencionista

C1131003 - AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA

Primary immune thrombocytopenia (ITP) is a blood condition that causes low levels of platelets, which are cells that help your blood clot. People with ITP often bruise easily or bleed more than usual. This Phase 2 study is testing an experimental medicine called PF-06835375. Researchers want to find out if this new injection can safely increase platelet counts in adults with moderate to severe ITP. Because this is an 'open-label' study, all participants will receive the study medicine at one of several planned doses—there is no dummy drug (placebo). Participants will also be given an allergy medicine (diphenhydramine) before their treatment to help prevent common injection reactions. Doctors will monitor participants closely over 12 to 16 weeks and beyond, checking their blood counts and watching for any side effects to see how well the treatment works.

De un vistazo

Estado
Reclutamiento
Fase
Exploratorio terapéutico (Fase II)
Patrocinador
Pfizer Inc.
Objetivo de inscripción
69
Inicio
03 Jun 2024

¿De qué trata este estudio?

Primary immune thrombocytopenia (ITP) is an autoimmune condition. In a healthy body, blood cells called platelets stick together to stop bleeding when you get a cut or bruise. If you have ITP, your immune system mistakenly attacks and destroys your own platelets. This leaves you with a low platelet count, which can lead to easy bruising, purple spots on the skin, nosebleeds, or more serious bleeding problems.

While there are existing treatments for ITP, they do not work for everyone, and some can cause difficult side effects. This clinical trial is testing a new injectable drug known as PF-06835375. Scientists have designed this medicine to calm the immune system's attack on platelets, aiming to let platelet numbers return to safer levels.

This study is a Phase 2 trial, which means researchers are working out how well the medicine works and finding the right dose. Participants will receive one of several dose amounts. Doctors will follow participants for several months, testing blood samples to see if their platelet counts rise and staying watchful for any unwanted side effects. Finding new and better ways to treat ITP could help people manage their condition with fewer bleeding risks.

Puntos clave

  • Tests a new injection (PF-06835375) designed to raise platelet counts in adults with ITP.
  • Open to adults aged 18 and older with moderate to severe primary ITP.
  • All participants receive the study drug; there is no dummy treatment (placebo).
  • Requires regular clinic visits for blood tests, injections, and safety checks over several months.
  • Participation is completely voluntary and you can leave the study at any time.

¿Quién puede ser elegible?

This study is open to adults aged 18 and older of any sex who have been diagnosed with moderate to severe primary immune thrombocytopenia (ITP). It is meant for people whose platelet counts remain low and who may need new treatment options.

To join, participants must be able to attend regular clinic appointments for injections, health checks, and blood tests.

Not everyone will be able to take part. People with certain other underlying medical conditions, active infections, or those taking specific medications that could clash with the study drug may not be eligible. The study doctor will review your full medical history and run tests to decide if the trial is safe for you.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. Are you aged 18 or older?
  2. Have you been diagnosed with primary immune thrombocytopenia (ITP)?
  3. Is your ITP currently considered moderate to severe?
  4. Are you willing to receive injections and have regular blood tests?
  5. Can you travel to a study centre for scheduled check-ups over several months?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you take part, you will visit a specialist hospital clinic regularly. During your visits, doctors and nurses will check your overall health, measure your vital signs, and take routine blood samples to monitor your platelet counts and immune cells. You will receive the study medicine as an injection. Before the injection, you may receive an antihistamine called diphenhydramine to help stop any mild allergic or infusion reactions. The main treatment phase lasts around 12 to 16 weeks, depending on the dose group you are in. After this, there will be follow-up checks so the medical team can see how you are doing over time.

Riesgos y beneficios potenciales

Taking part may help increase your platelet counts and lower your risk of bleeding, although this cannot be guaranteed. You will also receive very close medical care and monitoring from a team of blood specialists. However, there are potential risks. Because PF-06835375 is an experimental medicine, it may cause unforeseen side effects or allergic reactions. The allergy medicine given beforehand can also cause mild sleepiness or dry mouth. Regular blood tests may cause brief discomfort or bruising. Taking part is completely voluntary, and you can change your mind and leave the study at any time without it affecting your standard NHS care.

Locations (3)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    Polonia
  • —
    No verificado
    Chequia
  • —
    No verificado
    Hungría

Preguntas comunes

What is primary immune thrombocytopenia (ITP)?

ITP is a blood disorder where your immune system mistakenly destroys your platelets, making it harder for your blood to clot and increasing the risk of bruising and bleeding.

Will I receive a placebo (dummy medicine)?

No. This is an 'open-label' study, which means every participant receives the real study medicine, and both you and your doctor will know the dose you are getting.

Why is diphenhydramine given before the injection?

Diphenhydramine is a common antihistamine medicine. It is given to help prevent mild allergic symptoms or reactions that can sometimes happen when receiving an injection of a new medicine.

¿Cuánto tiempo estaré en el estudio?

The main part of the study lasts between 12 and 16 weeks, followed by further monitoring visits to check on your long-term health and platelet counts.

What happens if I want to stop taking part?

You can leave the trial at any time for any reason. Your regular doctors will support your decision and continue to provide standard treatment for your condition.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "C1131003 - AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENT…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.